SpaceLintech, a space pharmaceuticals specialist, announced Wednesday that it has signed a memorandum of understanding with AI semiconductor company Mobilint to jointly develop AI-based space payloads and advance high-performance, low-power AI semiconductor solutions optimized for space environments.
The partnership aims to combine both companies' core technologies to strengthen strategic cooperation across the space industry. The two firms will jointly develop AI space payloads utilizing Mobilint's neural processing unit (NPU) and optimize high-performance, low-power AI semiconductor solutions capable of stable operation in space environments. They plan to expand collaboration into various application areas linked to the space industry and build a long-term partnership centered on technology development and demonstration.
SpaceLintech has developed experimental platforms and payload technologies that automate pharmaceutical experiments in space environments. Recently, the company has been expanding its demonstration scope with next-generation space pharmaceutical experiment modules incorporating AI. Through this partnership, the company expects to strengthen data processing, monitoring, and autonomous operation capabilities for AI-based payloads, enhancing the efficiency and reliability of space experiments.
Mobilint possesses NPU-based semiconductor solutions optimized for edge AI environments and has been applying its high-performance, low-power AI computing technology across various industrial sectors. The two companies plan to jointly address technical challenges in implementing stable AI computing under space-specific constraints including power, thermal, and communication limitations, while systematically verifying applicability to the space industry.
"Space experiments and payload operations require high levels of automation and reliability in resource-constrained environments," said Yoon Hak-soon, CEO of SpaceLintech. "Through integration with Mobilint's high-performance, low-power NPU technology, we will strengthen our AI-based space payload demonstration capabilities and expand into a next-generation space bio research platform."
SpaceLintech recently accumulated operational experience in automated protein crystallization experiments by conducting demonstration of its space pharmaceutical research module 'BEE-PC1' on the International Space Station (ISS). The company subsequently launched its space bio research satellite 'BEE-1000,' establishing a satellite-based protein drug crystallization research framework. SpaceLintech has designated this year as the inaugural year for 'AI-based space pharmaceuticals' and plans to accelerate AI application research to improve process stability and reproducibility in microgravity environments.